University of Veterinary Medicine Vienna Anti-Cancer Potential of a new Derivative of Caffeic Acid Phenethyl Ester targeting the Centrosome Anaplastic Large Cell Lymphoma (ALCL) is an aggressive T-cell lymphoma affecting children and young adults. About 30% of patients develop therapy resistance therefore new precision medicine drugs are highly warranted. Multiple rounds of structure-activity optimization of Caffeic Acid Phenethyl Ester have resulted in CM14. CM14 causes upregulation of genes involved in oxidative stress response and downregulation of DNA replication genes leading to G2/M arrest and subsequent apoptosis induction. In accordance with this, an unbiased proteomics approach, confocal microscopy and molecular modeling showed that TUBGCP2, member of the centrosomal ?-TuRC complex, is a direct interaction partner of CM14. CM14 overcomes ALK inhibitor resistance in ALCL and is also active in T-cell Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia. Interestingly, CM14 also induced cell death in docetaxel-resistant prostate cancer cells thus suggesting an unexpected role in solid cancers. Thus, we synthesized and thoroughly characterized a novel TUBGCP2 targeting drug that is active in ALCL but has also potential for other malignancies. en TEXT journal article Wissenschaftlicher Artikel Articolo di rivista Text journal article Testo Articolo di rivista Text Wissenschaftlicher Artikel Humans Caffeic Acids Pharmacology Caffeic Acids Chemistry Phenylethyl Alcohol Analogs & Derivatives Phenylethyl Alcohol Pharmacology Phenylethyl Alcohol Chemistry Centrosome Drug Effects Centrosome Metabolism Antineoplastic Agents Pharmacology Antineoplastic Agents Chemistry Apoptosis Drug Effects Cell Line, Tumor Cell Proliferation Drug Effects 2025 2025 Catello Giordano Jonatan Kendler Maximilian Sexl Sebastian Kollman Maxim Varenicja Boglárka Szabó Gerald Timelthaler Dominik Kirchhofer Oldamur Hollóczki Suzanne D. Turner Richard Moriggl Lukas Kenner Mohamed Touaibia Olaf Merkel Elsevier